181 related articles for article (PubMed ID: 37861736)
21. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells.
Pennisi M; Sanchez-Escamilla M; Flynn JR; Shouval R; Alarcon Tomas A; Silverberg ML; Batlevi C; Brentjens RJ; Dahi PB; Devlin SM; Diamonte C; Giralt S; Halton EF; Jain T; Maloy M; Mead E; Palomba ML; Ruiz J; Santomasso B; Sauter CS; Scordo M; Shah GL; Park JH; Yanez San Segundo L; Perales MA
Blood Adv; 2021 Sep; 5(17):3397-3406. PubMed ID: 34432870
[TBL] [Abstract][Full Text] [Related]
22. Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma.
Nie EH; Su YJ; Baird JH; Agarwal N; Bharadwaj S; Weng WK; Smith M; Dahiya S; Han MH; Dunn JE; Kipp LB; Miklos DB; Scott BJ; Frank MJ
Blood Adv; 2024 Mar; 8(6):1474-1486. PubMed ID: 38295285
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study.
Epperla N; Feng L; Shah NN; Fitzgerald L; Shah H; Stephens DM; Lee CJ; Ollila T; Shouse G; Danilov AV; David KA; Torka P; Hashmi H; Hess B; Barta SK; Romancik JT; Cohen JB; Annunzio K; Kittai AS; Reneau J; Zurko J; Nizamuddin IA; Winter JN; Gordon LI; Ma S; Patel R; Nastoupil L; Ahmed S; Karmali R
J Hematol Oncol; 2023 Nov; 16(1):111. PubMed ID: 37946255
[TBL] [Abstract][Full Text] [Related]
24. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
[TBL] [Abstract][Full Text] [Related]
25. Host metabolome predicts the severity and onset of acute toxicities induced by CAR T-cell therapy.
Jalota A; Hershberger CE; Patel MS; Mian A; Faruqi A; Khademi G; Rotroff DM; Hill BT; Gupta N
Blood Adv; 2023 Sep; 7(17):4690-4700. PubMed ID: 36399526
[TBL] [Abstract][Full Text] [Related]
26. Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells.
Galli E; Sorà F; Hohaus S; Fresa A; Pansini I; Autore F; Metafuni E; Innocenti I; Limongiello MA; Giammarco S; Laurenti L; Bacigalupo A; Chiusolo P; De Stefano V; Sica S
Br J Haematol; 2023 Apr; 201(1):86-94. PubMed ID: 36503182
[TBL] [Abstract][Full Text] [Related]
27. Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma.
Zhou J; Zhang Y; Shan M; Zong X; Geng H; Li J; Chen G; Yu L; Xu Y; Li C; Wu D
Front Immunol; 2022; 13():997589. PubMed ID: 36131934
[TBL] [Abstract][Full Text] [Related]
28. Chimeric antigen receptor T-cell therapy: An emergency medicine focused review.
Long B; Yoo MJ; Brady WJ; Holian A; Sudhir A; Gottlieb M
Am J Emerg Med; 2021 Dec; 50():369-375. PubMed ID: 34461398
[TBL] [Abstract][Full Text] [Related]
29. [Toxicity after chimeric antigen receptor T-cell therapy : Overview and management of early and late onset side effects].
Garcia Borrega J; Heindel K; Göreci Y; Warnke C; Onur OA; Kochanek M; Schub N; Ayuk F; Wichmann D; Böll B
Internist (Berl); 2021 Jun; 62(6):611-619. PubMed ID: 34032877
[TBL] [Abstract][Full Text] [Related]
30. EEG before chimeric antigen receptor T-cell therapy and early after onset of immune effector cell-associated neurotoxicity syndrome.
Hernani R; Aiko M; Victorio R; Benzaquén A; Pérez A; Piñana JL; Hernández-Boluda JC; Amat P; Pastor-Galán I; Remigia MJ; Ferrer-Lores B; Micó M; Carbonell N; Ferreres J; Blasco-Cortés ML; Santonja JM; Dosdá R; Estellés R; Campos S; Martínez-Ciarpaglini C; Ferrández-Izquierdo A; Goterris R; Gómez M; Teruel A; Saus A; Ortiz A; Morello D; Martí E; Carretero C; Calabuig M; Tormo M; Terol MJ; Cases P; Solano C
Clin Neurophysiol; 2024 Jul; 163():132-142. PubMed ID: 38733703
[TBL] [Abstract][Full Text] [Related]
31. Double systemic cytokine release syndrome following sequential infusion of anti-CD22 and anti-CD19 chimeric antigen receptor T cells after autologous hematopoietic stem cell transplantation for a central diffuse large B-cell lymphoma patient: A case report and literature review.
Zheng J; Xiao Y; Wu XQ; Xiao QZ; Feng C; Gao KB
Front Immunol; 2023; 14():1098815. PubMed ID: 36798130
[TBL] [Abstract][Full Text] [Related]
32. CAR t-cell therapy in BOlogNa-NEUrotoxicity TReatment and Assessment in Lymphoma (CARBON-NEUTRAL): proposed protocol and results from an Italian study.
Pensato U; Amore G; Muccioli L; Sammali S; Rondelli F; Rinaldi R; D'Angelo R; Nicodemo M; Mondini S; Sambati L; Asioli GM; Rossi S; Santoro R; Cretella L; Ferrari S; Spinardi L; Faccioli L; Fanti S; Paccagnella A; Pierucci E; Casadei B; Pellegrini C; Zinzani PL; Bonafè M; Cortelli P; Bonifazi F; Guarino M
J Neurol; 2023 May; 270(5):2659-2673. PubMed ID: 36869888
[TBL] [Abstract][Full Text] [Related]
33. Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies.
Dos Santos DMC; Rejeski K; Winkelmann M; Liu L; Trinkner P; Günther S; Bücklein VL; Blumenberg V; Schmidt C; Kunz WG; Von Bergwelt-Baildon M; Theurich S; Subklewe M
Haematologica; 2022 Sep; 107(9):2096-2107. PubMed ID: 35172565
[TBL] [Abstract][Full Text] [Related]
34. Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma.
Zhang Q; Zu C; Jing R; Feng Y; Zhang Y; Zhang M; Lv Y; Cui J; Zhou L; Meng Y; Wang L; Cen Z; Chang AH; Hu Y; Huang H
Front Immunol; 2023; 14():1125357. PubMed ID: 37215107
[TBL] [Abstract][Full Text] [Related]
35. Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities.
de Boer JW; Keijzer K; Pennings ERA; van Doesum JA; Spanjaart AM; Jak M; Mutsaers PGNJ; van Dorp S; Vermaat JSP; van der Poel MWM; van Dijk LV; Kersten MJ; Niezink AGH; van Meerten T;
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001703
[TBL] [Abstract][Full Text] [Related]
36. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS).
Wehrli M; Gallagher K; Chen YB; Leick MB; McAfee SL; El-Jawahri AR; DeFilipp Z; Horick N; O'Donnell P; Spitzer T; Dey B; Cook D; Trailor M; Lindell K; Maus MV; Frigault MJ
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34996813
[TBL] [Abstract][Full Text] [Related]
37. [The critically ill CAR T-cell patient : Relevant toxicities, their management and challenges in critical care].
Garcia Borrega J; Heindel K; Kochanek M; Warnke C; Stemmler J; von Bergwelt-Baildon M; Liebregts T; Böll B
Med Klin Intensivmed Notfmed; 2021 Mar; 116(2):121-128. PubMed ID: 33564900
[TBL] [Abstract][Full Text] [Related]
38. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study.
Azoulay É; Castro P; Maamar A; Metaxa V; de Moraes AG; Voigt L; Wallet F; Klouche K; Picard M; Moreau AS; Van De Louw A; Seguin A; Mokart D; Chawla S; Leroy J; Böll B; Issa N; Levy B; Hemelaar P; Fernandez S; Munshi L; Bauer P; Schellongowski P; Joannidis M; Moreno-Gonzalez G; Galstian G; Darmon M; Valade S;
Lancet Haematol; 2021 May; 8(5):e355-e364. PubMed ID: 33894170
[TBL] [Abstract][Full Text] [Related]
39. Identification of Neurotoxicity after Chimeric Antigen Receptor (CAR) T Cell Infusion without Deterioration in the Immune Effector Cell Encephalopathy (ICE) Score.
Herr MM; Chen GL; Ross M; Jacobson H; McKenzie R; Markel L; Balderman SR; Ho CM; Hahn T; McCarthy PL
Biol Blood Marrow Transplant; 2020 Nov; 26(11):e271-e274. PubMed ID: 32736009
[TBL] [Abstract][Full Text] [Related]
40. How I treat refractory CRS and ICANS after CAR T-cell therapy.
Jain MD; Smith M; Shah NN
Blood; 2023 May; 141(20):2430-2442. PubMed ID: 36989488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
